Improving Diabetes After Bariatric Surgery

University of Pittsburgh63 enrolled

Overview

The goal of this project is to examine the physical mechanisms that contribute to improvements of glucose tolerance in type 2 diabetes mellitus (DM) following certain types of bariatric surgery.

The goal of this project is to examine the physiological mechanisms that contribute to improvements of glucose homeostasis in type 2 diabetes mellitus (DM) following gastric bypass Roux-en-Y bariatric surgery (GBP). The central hypotheses are: 1) that surgical changes in the anatomy of nutrient absorption achieved by GBP change incretin hormone secretion which in turn improves pancreatic islet function; and 2) that improvement in insulin secretion induced by the changes in incretin function, together with improvement in insulin resistance induced by weight loss, normalize glucose homeostasis in type 2 DM. Funds are not available to pay for the surgery for patients, only to address research questions.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Obesity Diabetes

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Patients who are at least 18 years of age and undergo bariatric surgery by a LABS certified surgeon. * Enrollment in LABS-1 or LABS-2. * Documented type 2 diabetes (fasting plasma glucose greater than 125 mg/dl) that is treated with lifestyle efforts (drug naïve) or taking acceptable oral medications (see appendix) with a HgA1c less than or equal to 8.5% and a fasting blood glucose less than or equal to 180 mg/dL. This will be one group. * Non-diabetic (ND) with normal values for fasting glucose and HbA1c. This will be the second group. * Adequate IV access. Exclusion Criteria: * Informed consent not obtained. * Patient with diabetes with an HbA1c greater than 8.5% or a fasting blood glucose greater than 180 mg/dL. * Creatinine greater than 1.7. * Unlikely to comply with the 6 month follow-up (post-surgical) protocol (i.e. geographically inaccessible for study visits) or unable to communicate with local study staff. * Use of unacceptable diabetic medications (see appendix) at baseline (see appendix).

Locations (5)

Legacy Good Samaritan Hospital

Portland, Oregon, United States

Oregon Health and Science University

Portland, Oregon, United States

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, United States

University of Washington

Seattle, Washington, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.